Table 1A.

Detailed clinical data of the 14 MuSK-MG patients.

Patient number	1	2	3	4	5	6	7
Sex	Female	Female	Female	Male	Female	Female	Female
Onset age (years)	53	62	71	70	63	34	64
MuSK Ab titer (U/ml)	4.45	>12.00	>12.00	3.63	5.48	5.47	1.01
Disease duration (months)	17	74	4	96	78	25	38.5
Onset symptom	Ptosis, slurred speech	Dysphagia, slurred speech	Dyspnea	Slurred speech, dysphagia	Slurred speech	Diplopia	Limb weakness
Tongue muscle atrophy	Yes	Yes	No	Yes	No	No	No
Jolly test	Positive	Negative	Positive	Positive	Positive	Positive	Positive
Time from onset to involvement of other muscle groups (months)	10.5	71	2	90	60	–	12
Most severe Osserman classification	IIb	IIb	III	IIb	IV	I	IV
Maximum QMG scores	13	21	22	10	24	4	24
Time from onset to the peak (months)	17	72	3.2	96	73.5	0.3	37.5
Number of myasthenic crisis	0	0	1	0	1	0	2
Neostigmine trial	Positive	Negative	Negative	Positive	Positive	Positive	Negative
Cholinergic side effect	Yes	Yes	Yes	No	Yes	No	Yes
Decrement on RNS (3 Hz)	Yes	Yes	Yes	Not done	Not done	No	No
Thymus CT scan/pathology	Normal	Normal	Normal	Normal	Normal	Normal	Normal
TG/TPO Ab	Normal	Increased	Increased	Normal	Increased	Normal	Increased
Other AD	Hyperthyroidism	No	Hashimoto thyroiditis	No	No	Behcet's disease	Hashimoto thyroiditis
Intravenous immunoglobulin	Yes	No	No	No	Yes	No	Yes
Glucocorticoid	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Tacrolimus	Yes	Yes	Yes	Yes	Yes	Yes	No
Pyridostigmine bromide	30 mg tid	No	No	60 mg tid	No	60 mg tid	No
Follow-up time (months)	12	12	21	3	1	42	0.25
QMG scores after treatment	5	4	5	4	15	0	–
Prognosis	Markedly effective	Basically cured	Markedly effective	Markedly effective	Effective	Cured	Died